title: [Indications and methods for adjuvant chemotherapy of colonic cancer].
abstract: Within the past 12 years, many progresses have been performed in adjuvant chemotherapy of colon cancer. 5FU + levamisole was first considered as standard treatment in the early 1990s, then FUFOL and later LV5FU2. More recently, FOLFOX4 achieves a better disease-free survival at 3 years as compared to LV5FU2, and should now be considered as a standard treatment. Adjuvant chemotherapy is recommended for 6 months for stage III patients. It is an option for stage II patients. Elderly patients could be treated according to the same modalities as younger patients, based on physiological age and relative contra-indications from associated diseases.
authors.affiliation: Service d'oncologie, Hôpital Saint-Antoine, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France. christophe.louvet@sat.ap-hop-paris.fr
authors.forename: C
authors.initials: C
authors.lastname: Louvet
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant / Q000379:methods; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery / Q000628:therapy; D000075202:Contraindications; D006801:Humans; D007167:Immunotherapy; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009367:Neoplasm Staging; D018365:Neoplasm, Residual / Q000188:drug therapy; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin